Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival.

被引：0
|
作者：
Freedland, S. J.
Humphreys, E. B.
Mangold, L. A.
Eisenberger, M.
George, D. J.
Partin, A. W.
机构：
[1] Duke Univ, Durham, NC USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：233S / 233S
页数：1
相关论文
共 50 条
  • [1] Prostate specific antigen doubling time after radical prostatectomy as a predictor of cause specific survival
    Partin, AW
    Humphreys, EB
    Mangold, LA
    Klicos, N
    Eisenberger, M
    Walsh, PC
    JOURNAL OF UROLOGY, 2004, 171 (04): : 382 - 382
  • [2] PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
    Markowski, Mark C.
    Chen, Yongmei
    Feng, Zhaoyong
    Cullen, Jennifer
    Trock, Bruce J.
    Suzman, Daniel
    Antonarakis, Emmanuel S.
    Paller, Channing J.
    Rosner, Inger
    Han, Misop
    Walsh, Patrick C.
    Partin, Alan W.
    Eisenberger, Mario
    CLINICAL GENITOURINARY CANCER, 2019, 17 (06) : 470 - +
  • [3] USE OF ULTRASENTIVE PSA DOUBLING TIME TO ESTIMATE PROGRESSION RISK OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
    Seikkula, Heikki
    Kurki, Samu
    Syvanen, Kari
    Bostrom, Peter
    Laato, Matti
    JOURNAL OF UROLOGY, 2014, 191 (04): : E858 - E858
  • [4] Time to PSA recurrence after radical prostatectomy and risk of prostate cancer specific mortality
    Freedland, SJ
    Humphreys, EB
    Mangold, LA
    Eisenberger, M
    Partin, AW
    JOURNAL OF UROLOGY, 2006, 175 (04): : 382 - 382
  • [5] PSA doubling time is not a surrogate for prostate-cancer-specific survival
    Nature Clinical Practice Oncology, 2007, 4 (2): : 69 - 69
  • [6] PSA doubling time is not a surrogate for prostate-cancer-specific survival
    Nature Clinical Practice Urology, 2007, 4 (3): : 118 - 118
  • [7] Impact of Elevated PSA, and Prostate Cancer in ESRD on Time to Transplant, and Survival.
    Sarabu, N.
    Schiltz, N.
    Hricik, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 303 - 304
  • [8] PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer
    Roberts, SG
    Blute, ML
    Bergstralh, EJ
    Slezak, JM
    Zincke, H
    MAYO CLINIC PROCEEDINGS, 2001, 76 (06) : 576 - 581
  • [9] ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer
    Hoogland, A. Marije
    Jenster, Guido
    van Weerden, Wytske M.
    Trapman, Jan
    van der Kwast, Theo
    Roobol, Monique J.
    Schroeder, Fritz H.
    Wildhagen, Mark F.
    van Leenders, Geert J. L. H.
    MODERN PATHOLOGY, 2012, 25 (03) : 471 - 479
  • [10] ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer
    Hoogland, A. M.
    Jenster, G.
    Van Weerden, W. M.
    Trapman, J.
    Van der Kwast, T.
    Roobol, M. J.
    Schroder, F. H.
    Wildhagen, M. F.
    Van Leenders, G. J. L. H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E425 - U932
12345